Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Biocept, Inc. logo — Helping physicians improve outcomes for metastatic cancer pa...

Biocept, Inc.

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic testing solutions.

Founded 1993 United States San Diego, United States 49 employees Post Ipo Equity Total: $48.20M Biotechnology, Health Care

General Information

Company Name Biocept, Inc.
Founded Year 1993
Location United States San Diego, United States +1
Founders / Decision Makers
Team member
Employees 49
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Biocept, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Biocept, Inc.

Biocept, Inc. is a biotechnology company based in the United States, founded in 1993 with a focus on providing advanced diagnostic testing solutions for metastatic cancer patients. Their CNSide™ assay offers enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid, aiding in the evaluation of treatment response and characterization of genetic changes associated with therapy resistance. Their CLIA-certified and CAP-accredited laboratory is dedicated to helping oncologists manage the complexities of cancer, addressing critical questions related to treatment and response trends. The company recently received a $5.00 million post-IPO equity investment on May 24, 2023. This investment will likely support the expansion of their diagnostic testing solutions and contribute to their ongoing efforts to improve outcomes for cancer patients. Biocept's dedication to improving cancer care and the provision of RT-PCR based COVID-19 testing to support public health efforts demonstrates their commitment to impacting healthcare on a broader scale. With a focus on biotechnology and healthcare, Biocept, Inc. exemplifies a forward-thinking approach to diagnostic solutions in the field of oncology.

Taxonomy: clinical laboratory tests, oncology testing, liquid biopsy, metastatic cancer, diagnostic assays, cell separation technology, cancer diagnostics, clinical services, molecular testing, COVID-19 testing, genetic markers, personalized medicine, rare cell analysis, cerebrospinal fluid (CSF) testing

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 24 May 2023
Post-IPO Equity •••••• - 30 Jan 2018
Post-IPO Equity •••••• 2
Investor
•••• •••• 		28 Mar 2017
Debt Financing •••••• - 16 Feb 2011
Series B •••••• - 12 Aug 2010

View All 8 Funding Rounds

Biocept, Inc. Alternatives & Competitors

Biocept, Inc. vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre Seed
38 employees
Biotechnology, Health Care
Compare Biocept, Inc. vs Farcast Biosciences
Biocept, Inc. vs
Clearity
Clearity United States

For life with ovarian cancer.

19 employees
Biotechnology, Health Care
Compare Biocept, Inc. vs Clearity
Biocept, Inc. vs
AgonOx, Inc.
AgonOx, Inc.

DISCOVERING AND DEVELOPING NEW IMMUNOTHERAPY AGENTS TO IMPROVE THE LIVES OF THOSE LIVING WITH CANCER...

5 employees
Biotechnology, Pharmaceutical
Also compare with: Biocept, Inc. vs VitroScan VitroScan

FAQ About Biocept, Inc.

Helping physicians improve outcomes for metastatic cancer patients by delivering advanced diagnostic testing solutions.
Biocept, Inc. was founded in 1993.
Biocept, Inc. is headquartered in San Diego, United States.
Biocept, Inc. operates in the following industries: Biotechnology, Health Care.
Biocept, Inc. has approximately 49 employees.
Biocept, Inc. has completed 8 funding rounds, raising a total of $48.20M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Biocept, Inc. include Farcast Biosciences, Clearity, AgonOx, Inc., VitroScan, EV Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biocept, Inc. and Farcast Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Biocept, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy